

Neuroprotection

Models, Mechanisms and Therapies

Edited by

Mathias Bähr



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

**Neuroprotection
Models, Mechanisms
and Therapies**

*Edited by
Mathias Bähr*

Further Titles of Interest

O. von Bohlen und Halbach, R. Dermietzel

Neurotransmitters and Neuromodulators

2002

ISBN 3-527-30318-9

R. Webster (Ed.)

Neurotransmitters, Drugs and Brain Function

2002

ISBN 0-471-97819-1

L. D. Miller, R. L. Hayes, J. K. Newcomb

Head Trauma: Basic, Preclinical, and Clinical Directions

2001

ISBN 0-471-36015-1

R. Shulman, D. Rothman (Eds.)

Brain Energetics and Neuronal Activity: Applications to MRI and Medicine

2004

ISBN 0-470-84720-4

P. Tofts (Ed.)

Quantitative MRI of the Brain: Measuring Changes caused by Disease

2003

ISBN 0-470-84721-2

C. U. M. Smith

Elements of Molecular Neurobiology, Third Edition

2002

ISBN 0-470-84353-5

Neuroprotection

Models, Mechanisms and Therapies

Edited by

Mathias Bähr



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Editor:

Prof. Dr. Mathias Bähr
Department of Neurology
University of Göttingen Medical School
Robert-Koch-Str. 40
37075 Göttingen
Germany

Cover Illustration

The cover picture shows an MR scan of an Multiple Systems Atrophy patient with cerebellar and brain-system involvement (Courtesy of the Editor).

This book was carefully produced. Nevertheless, authors, editor and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for
A catalogue record for this book is available from the British Library.

**Bibliographic information published by
Die Deutsche Bibliothek**
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.
Printed on acid-free paper.

Typesetting hagedorn kommunikation,
Viernheim
Printing betz-druck gmbh, Darmstadt
Bookbinding Litges & Dopf Buchbinderei
GmbH, Heppenheim

ISBN 3-527-30816-4

Preface

In the last decades, the scientific community as well as the public has been overwhelmed with a tremendous amount of data on the cellular, molecular and physiological mechanisms of neuronal proliferation, differentiation, maintenance and degeneration. A plethora of animal models of various neurological disorders has been introduced and used to delineate the mechanisms of cell death and highlight potential targets for neuroprotective or neurorestorative intervention strategies. With great enthusiasm, the complete deciphering of the human genome and the genetic information of various other species has been announced and raised the hope of a final victory over many fatal human diseases. Findings about the genetic or molecular causes of human disorders that were reproduced in animals and positive results from experimental therapies were generalized for human patients, and new experimental treatments were quickly transferred to clinics, sometimes speeded up by high expectations of the public as well as managers from pharmaceutical companies.

However, by the same token, many clinical studies which were introduced on the basis of positive data with new pharmacological substances or effective procedures in animal models did not show positive results in humans, and several trials had to be stopped, due to adverse effects which led to a significant deterioration in some patients.

From a multitude of substances tested in basic research models, only few have reached clinical testing in patients thus far. Among those substances are neurotrophic factors, mitochondria-stabilizing agents, anti-oxidants, anti-toxins, antibiotics, glutamate receptor and calcium channel blockers as well as caspase-inhibitors (Kermer and Bähr, 2002). However, none of them has so far led to a substantial breakthrough in neurological or psychiatric therapy. Thus, one has to ask why so many promising drugs with positive effects in basic research models failed in the clinic. This is not easy to understand, and there is certainly not a single answer. However, some general aspects can be mentioned which are discussed in more detail in the various chapters of this book:

First of all, in animal models, the modes of application, the delay between onset of a pathology and therapy and many side effects are completely different to the human situation. Thus, a substance may show a profound effect after intraparenchymal or intraventricular application minutes after onset of ischemia in animals, but the systemic application hours after onset of a stroke in humans does

not result in a timely and quantitatively sufficient concentration in the affected region or cell in the CNS.

Secondly, as mentioned earlier, in standardized animal models, mostly young and otherwise healthy rodents are used. In contrast, patients with neurological disorders, e. g. stroke, are often old with a substantial co-morbidity, which may result in many cross-reactions of a new drug with existing medications and adverse effects that can not be anticipated in young and healthy animals. Finally, the time of onset, the course and the outcome of a given insult vary substantially in patients and, depending on the selection criteria for clinical studies, a potentially effective drug may be given to patients where there is nothing left to rescue at all, or the criteria which are used in animals to demonstrate efficacy are not available for patients (e. g. histological measure of cell survival rates or tissue preservations in animal models which can not be applied in human patients).

As a consequence, the whole concept of developing or introducing new drugs on the basis of animal (model) data was challenged, and many big pharmaceutical companies stopped or significantly reduced their efforts to develop new “neuroprotective” substances in their basic research departments.

Thus, it appears to be timely to present a comprehensive review on our current knowledge in the field to analyse the potential as well as the limitations of the available model systems for many highly relevant neurological disorders such as stroke, trauma, neurodegenerative disorders or inflammatory diseases of the CNS. Furthermore, it seems to be necessary to have a closer look at some general problems that evolve when data from animals, mostly young and healthy rodents, are to be translated into clinical settings in order to learn from the errors for our future planning of neuroprotective or neurorestorative therapies.

Finally, new results from basic as well as applied research need to be presented and evaluated which may open completely new avenues for future therapy concepts. To that end, internationally recognized outstanding experts in their respective fields from several countries have contributed to this first edition of Neuroprotection – Models – Mechanisms – Therapies.

We hope that this book provides a guideline for non-experts for a better understanding of the complexity of data that are generated in basic research experiments and the pitfalls of translational research on the one hand and a detailed overview and basis for discussions and future developments in the field for academics involved in basic research or applied neurosciences on the other.

Göttingen, January 2004

Mathias Bähr

Acknowledgements

The launch of a new book is a multifaceted task which can only be accomplished by team work. I would like to thank all the people who contributed to this book, especially my secretaries Mrs. Heidi Gottfried and Mrs. Barbara Nordmann as well as Dr. Andreas Sendtke from Wiley-VCH.

**I Neurological Disorders – Epidemiology, Clinical Overview,
and Model Systems**

1. Stroke
2. Parkinson's Disease
3. Amyotrophic Lateral Sclerosis
4. Alzheimer's Disease and Other Neurodegenerative Diseases
5. CNS Inflammation
6. Neurotrauma
7. Spinal Cord Injury

II Cellular and Molecular Mechanisms

8. Apoptosis and Necrosis
9. Inflammation
10. Metabolic Dysfunctions
11. Protein Misfolding
12. Axonal Growth Inhibition
13. Neurogenesis
14. Excitotoxicity

III Therapies

15. Spinal Cord Trauma
16. Neurodegeneration
17. Perspectives for Neuroprotective Therapies in Basic Research
and Clinical Application

Contents

Preface V

List of Contributors XVII

I Neurological Disorders – Epidemiology, Clinical Overview, and Model Systems

1 Stroke 3

Andreas Meisel, Konstantin Prass, Tilo Wolf, Ulrich Dirnagl

Abstract 3

1.1 Introduction 3

1.2 The Penumbra Concept 6

1.3 Excitotoxicity 7

1.4 Oxygen Free Radicals 7

1.5 Tissue Acidosis 8

1.6 Peri-infarct Depolarizations 9

1.7 Inflammation 10

1.8 Damage to the Blood–Brain-Barrier 12

1.9 Programmed Cell Death and Apoptosis 13

1.10 Ischemia-induced DNA Damage, DNA Repair, and p53 as Genotoxic Sensor 15

1.11 Epigenetics 17

1.12 Gene Expression 18

1.13 Cell Replacement 19

1.14 Endogenous Neuroprotection – Ischemic Tolerance 21

1.15 Stroke Induced Immune Depression (SIDS) 22

1.16 Conclusion 23

References 24

2 Parkinson's Disease 31

Marina Romero-Ramos, Matthew Maingay and Deniz Kirik

2.1 Epidemiology of Parkinson's Disease 32

2.1.1 Genetic Contribution 32

- 2.1.2 Environmental Factors 33
- 2.2 Oxidative Stress In Parkinson's Disease 34
- 2.3 Role of Alpha-Synuclein in Parkinson's Disease 35
 - 2.3.1 Alpha-Synuclein in Lewy Bodies 35
 - 2.3.2 Alpha-Synuclein and Oxidative Stress 36
- 2.4 The Involvement of Proteasome in PD 38
 - 2.4.1 Parkin Involvement in PD 39
- 2.5 Other Genes Involved in Familial Parkinson's Disease 41
- 2.6 Neurotoxic PD Models 41
 - 2.6.1 Oxidative Stress 42
 - 2.6.2 Dopamine Homeostasis/Complex I 42
 - 2.6.3 Proteasome 43
- 2.7 Genetic Models of Parkinson's Disease 43
 - 2.7.1 Alpha-Synuclein Overexpressing Transgenic Animals 43
 - 2.7.2 Parkin-related Genetic Models 44
 - 2.7.3 Viral Vectors for *In Vivo* Gene Transfer of Disease-related Proteins to the CNS 45
 - 2.7.3.1 Local Overexpression of alpha-synuclein 45
 - 2.7.3.2 Local Overexpression of Parkin-related Proteins 47

Acknowledgements 47

References 47

3 Amyotrophic Lateral Sclerosis 51

Georg Haase

- 3.1 Human Motor Neuron Diseases 51
 - 3.1.1 Familial ALS Linked to SOD1 Mutations 52
 - 3.1.2 Juvenile ALS Linked to Alsin Mutations 53
- 3.2 Cell Culture Models of Motoneuron Degeneration 53
 - 3.2.1 Neuronal Cell Lines 53
 - 3.2.2 Isolated Motoneuron Cultures 54
 - 3.2.3 Organotypic Cultures 55
- 3.3 Animal Models of Motor Neuron Disease 55
 - 3.3.1 Axotomy Models 56
 - 3.2 Mutant SOD1 Mice 56
 - 3.3.3 *pmn* Mice 61
- 3.4 Future Neuroprotective Approaches 62
 - 3.4.1 Axonal Protection 62
 - 3.4.2 Mutant SOD1 Knockdown by RNA Interference 63
- 3.5 Conclusion 63

References 63

4 Alzheimer's Disease and Other Neurodegenerative Diseases 71

Philipp J. Kahle and Christian Haass

Abstract 71

- 4.1 Introduction 72

- 4.2 Transgenic Invertebrates 72
- 4.3 Transgenic Mice 73
 - 4.3.1 Tyrosine Hydroxylase (TH) Promoter 73
 - 4.3.2 Platelet-derived Growth Factor- β (PDGF β) Promoter 74
 - 4.3.3 Thy1 Promoter 74
 - 4.3.4 Prion Protein (PrP) Promoter 75
 - 4.3.5 Glial Expression 76
- 4.4 Viral Models 77
- 4.5 Conclusion and Outlook 78
- References 78

5 CNS Inflammation 85

Christine Stadelmann and Wolfgang Brück

- 5.1 Introduction 85
- 5.2 The Pathologic Characteristics of the MS Plaque 86
- 5.3 Axonal Pathology in MS 87
- 5.4 Neuronal Pathology in Multiple Sclerosis 88
- 5.5 Lessons from Animal Models 89
- References 90

6 Neurotrauma 95

Ibolja Cernak, Paul M. Leavitt, Alan I. Faden

- 6.1 Introduction 95
- 6.2 *In Vivo* Models 96
 - 6.2.1 Static Brain Injury Models 97
 - 6.2.2 Dynamic Brain Injury Models 97
 - 6.2.2.1 Indirect Dynamic Brain Injury 97
 - 6.2.2.2 Direct Dynamic Brain Injury 98
 - 6.2.3 Combined Neurotrauma Models 106
- 6.3 *In Vitro* Models 106
 - 6.3.1 Tension Stress-induced Injury 109
 - 6.3.1.1 Stretch Injury Models 109
 - 6.3.2 Compression Injury Models 110
 - 6.3.2.1 Weight-drop Model 111
 - 6.3.2.2 Hydrostatic Pressure Models 111
 - 6.3.2.3 Fluid-percussion Models 111
 - 6.3.3 Shear Injury Models 112
 - 6.3.3.1 Acceleration Models 112
 - 6.3.3.2 Hydrodynamic Model 112
 - 6.3.3.3 Primary Axotomy/Transection Models 113
- 6.4 Conclusion 114
- References 115

7	Spinal Cord Injury	129
	<i>Poonam Verma and James W. Fawcett</i>	
7.1	Acute Neuroprotection (preventing neuronal death)	131
7.2	Regeneration of Nerve Fiber Tracts (initiating growth following injury)	132
7.2.1	Extrinsic Mechanisms	132
7.2.1.1	The Glial Scar	133
7.2.1.2	Blockage of Glial Scar Formation	133
7.2.1.3	Modification of Growth-inhibitory Molecules	134
7.2.1.4	Selective Removal of Astrocytes	136
7.2.2	Intrinsic Neuronal Control of Regeneration	136
7.2.2.1	Neuronal Age	137
7.2.2.2	Site of Transection	137
7.2.2.3	Neuronal Variability	138
7.3	Bridging Cysts and Scars and Cellular Replacement	138
7.4	Replacing Lost Neurons	139
7.4.1	Neural Transplantation	139
7.4.2	Replacing Lost Neurons from Stem Cells	140
7.5	Treating Demyelination	140
7.6	Enhancing Plasticity	141
7.7	Future Expectations	142
	References	143
II	Cellular and Molecular Mechanisms	
8	Apoptosis and Necrosis	153
	<i>Laura Korhonen and Dan Lindholm</i>	
8.1	Introduction	153
8.2	Apoptosis <i>versus</i> Necrosis	154
8.3	Genetics of Apoptosis and the Proteins Involved	155
8.3.1	<i>Caenorhabditis Elegans</i> as a Model System	155
8.3.2	Caspases	157
8.3.3	Anti-apoptotic Proteins	159
8.4	Cellular Mechanisms of Apoptosis	164
8.4.1	The Role of Mitochondria and the Apoptosome Complex	164
8.4.2	Cell Death in Neurodegenerative Diseases	166
	References	167
9	Inflammation	173
	<i>Harald Neumann</i>	
9.1	Introduction	173
9.2	Innate Immune Responses in the CNS	175
9.3	Dual Mechanism of Innate Immunity in the CNS	176
9.4	Antigen Presentation for Adaptive Immune Responses in the CNS	177
9.5	Regulation of Adaptive Immune Responses in the CNS	178

9.6	Immune Surveillance of the CNS by T Lymphocytes	180
9.7	Effector Mechanisms of Lymphocytes	181
	Acknowledgement	184
	References	187
10	Metabolic Dysfunctions	191
	<i>Konstantin-A. Hossmann</i>	
10.1	Introduction	191
10.2	Disturbances of the Energy Metabolism	192
10.2.1	Energy Production and Turnover	192
10.2.2	Reduction of Oxygen Supply	192
10.3	Disturbances of Flow-coupling	194
10.4	Mitochondrial Dysfunction	195
10.5	Importance of Disturbed Energy Metabolism for Injury Evolution	196
10.5.1	Global Brain Ischemia	196
10.5.2	Focal Brain Ischemia	198
10.5.3	Epileptic Seizures	200
10.5.4	Head Trauma	201
10.6	Disturbances of Protein Synthesis	202
10.6.1	Mechanisms of Disturbed Protein Synthesis	202
10.7	Importance of Disturbed Protein Synthesis on Injury Evolution	204
10.7.1	Global Brain Ischemia	204
10.7.2	Focal Ischemia	205
10.7.3	Epileptic Seizures	207
10.7.4	Head Trauma	207
10.8	Therapeutical Implications	208
	References	210
11	Protein Misfolding	213
	<i>Milene Russelakis-Carneiro, Claudio Hetz, Joaquin Castilla and Claudio Soto</i>	
	Abstract	213
11.1	Introduction	213
11.2	Disease Propagation by Replication of Prion Protein Misfolding	214
11.3	Prion Biology	215
11.4	Prion Pathogenesis	218
11.5	Neuronal Targeting	219
11.6	Neuronal Apoptosis in Prion Diseases	219
11.7	ER-Stress and Apoptosis in Prion Diseases	220
11.8	Concluding Remarks	223
	References	224
12	Axonal Growth Inhibition	229
	<i>Anne D. Zurn and Christine E. Bandtlow</i>	
12.1	Introduction	229
12.2	Intrinsic Properties of CNS Neurons	229

12.2.1	Survival of Injured Neurons	229
12.2.2	Developmental Loss Of Regenerative Ability	230
12.2.3	Intrinsic Differences in Growth Potential	231
12.2.4	Transient Expression of Growth-associated Molecules	231
12.2.5	Conditioning Lesion	232
12.3	Extrinsic Factors: The CNS as A Non-conductive Growth Environment	233
12.3.1	Cellular Components of Inhibition	233
12.3.1.1	The Glial Scar	233
12.3.1.2	Oligodendrocytes and Myelin (Wallerian Degeneration)	234
12.3.1.3	Secondary Injury: Inflammation, Cell-mediated Immunity, and Glial Cell Loss	235
12.3.1.4	Genetic Influences on Cellular Reactions to CNS Injury	236
12.3.2	Molecular Components of Inhibition	236
12.3.2.1	Axon growth Inhibitors in the Glial Scar	236
12.3.2.2	Myelin-associated Growth Inhibitors	239
12.3.3	Transduction of Axon Growth-inhibitory Signals	242
12.3.3.1	Receptors for Myelin-associated Inhibitors	242
12.3.3.2	Signaling Pathways of Myelin-associated Inhibitors	243
12.4	Experimental Strategies to Overcome Growth Inhibition	245
12.5	Conclusion	247
	References	248

13 Neurogenesis 261

Sebastian Jessberger and Gerd Kempermann

13.1	Introduction	261
13.2	Neural Stem- and Precursor Cells in the Adult Brain	263
13.2.1	Neural Stem Cells in the Adult Brain: <i>In vitro</i>	263
13.2.2	Neural Stem Cells In The Adult Brain: <i>In vivo</i>	264
13.3	Maturation and Migration of Adult-generated Neurons in the Adult Brain	266
13.4	Neurogenesis in the Adult Brain – Age Dependency, Persistence and Genetic Determinants	269
13.4.1	Neurogenesis in Aged Animals	269
13.4.2	Long-term Persistence of Adult-generated Neurons in the SVZ and Hippocampus	269
13.4.3	Genetic Influence on Adult Hippocampal Neurogenesis	270
13.5	Regulation of Adult Neurogenesis	270
13.5.1	Learning	271
13.5.2	Environmental Enrichment	271
13.5.3	Physical Activity	272
13.5.4	Stress and Depression	273
13.5.5	Epilepsy	274
13.5.6	Ischemia and Cortical Trauma	275
13.6	Possible Functional Relevance of Neurogenesis in the Adult Brain	276
13.7	Therapeutic Strategies for Neural Cell Replacement	278

- 13.7.1 Endogenous Neurogenesis 278
- 13.7.2 Transplantation of Stem- or Precursor Cells into the Damaged Brain 278
 - Acknowledgements 280
 - References 280

14 Excitotoxicity 291

Stuart A. Lipton, MD, PhD

Abstract 291

- 14.1 Introduction 292
- 14.2 The Search for Clinically-Tolerated NMDA Receptor Antagonists 293
- 14.3 Excitotoxicity 294
 - 14.3.1 Definition and Clinical Relevance 294
 - 14.3.2 Links between Stroke and Vascular Dementia to Excitotoxic Damage 295
 - 14.3.2.1 Possible Links between Excitotoxic Damage and Alzheimer's Disease 296
 - 14.3.3 Pathophysiology of Excitotoxicity: Role of the NMDA Receptor 296
 - 14.3.3.1 The Importance of Off-Rate from Channel Block 299
- 14.4 Memantine 300
 - 14.4.1 Background and Pharmacology: Uncompetitive Open-channel Block 300
 - 14.4.2 Voltage Dependence, Partial Trapping, and Other Possible Effects of Memantine 303
 - 14.4.3 Neuroprotective Efficacy 304
- 14.5 NitroMemantines 306
- 14.6 Summary 307
 - Acknowledgments 308
 - Appendix 308
 - References 309

III Therapies

15 Spinal Cord Trauma 317

V. Dietz

Abstract 317

- 15.1 Epidemiology 318
- 15.2 Clinical Aspects 318
 - 15.2.1 Acute Stage 318
 - 15.2.2 Dysfunction of the Autonomic Nervous System 319
 - 15.2.3 The Evolution of Signs and Symptoms 320
- 15.3 Principles of Therapy 321
 - 15.3.1 General Concepts 321
 - 15.3.2 Transition from Acute Care to Rehabilitation 322
 - 15.3.3 Basic Aspects of Motor Rehabilitation: Neuronal Activity of the Isolated Spinal Cord 322
- 15.4 Current Approaches in Motor Rehabilitation 323
 - 15.4.1 Spinal Reflex Plasticity 324
 - 15.4.2 Use-Dependent Plasticity – Rehabilitative Approaches 324

- 15.4.3 Task-specific Plasticity 325
- 15.4.4 Effects of Locomotor Training in Spinal Cord Injury 325
- 15.5 Search for Reliable Clinical Assessment 327
- 15.5.1 Physical Signs and Function 327
- 15.5.2 Appropriate Assessment of Function –
Basis for New Interventional Therapies 328
- 15.6 Conclusion 330
- References 331

16 Neurodegeneration 335

Jörg B. Schulz, MD

- 16.1 What Is Neuroprotection? 335
- 16.2 Outcome Measures in Clinical Studies 336
- 16.3 Specific Diseases 337
- 16.3.1 Wilson's Disease 337
- 16.3.2 Parkinson's Disease 338
- 16.3.2.1 DATATOP Study 338
- 16.3.2.2 Dopamine Agonists 338
- 16.3.2.3 Anti-Excitotoxic Treatment 339
- 16.3.2.4 Neurotrophins 339
- 16.3.2.5 MAP Kinase Inhibitors 340
- 16.3.2.6 Transplantation 340
- 16.3.2.7 Deep Brain Stimulation 341
- 16.3.2.8 Coenzyme Q₁₀ 341
- 16.3.3 Multiple System Atrophy and Progressive Supranuclear Palsy 341
- 16.3.4 Alzheimer's Disease 342
- 16.3.4.1 Symptomatic Treatment 342
- 16.3.4.2 Antioxidants 343
- 16.3.4.3 Anti-inflammatory Approaches 343
- 16.3.4.4 Estrogen Replacement 343
- 16.3.4.5 NMDA Receptor Antagonists 344
- 16.3.4.6 Experimental Therapies 344
- 16.3.4.7 Immunization 344
- 16.3.4.8 Cholesterol-lowering Therapy 346
- 16.3.5 Huntington's Disease 347
- 16.4 Why Do So Many Clinical Studies Fail? What Do We Need? 348
- References 349

**17 Perspectives for Neuroprotective Therapies in Basic Research
and Clinical Application 357**

Mathias Bähr and Pawel Kermer

References 360

Index 361

List of Contributors

Mathias Bähr
University of Göttingen
Department of Neurology
Robert-Koch-Str. 40
D-37075 Göttingen
Germany

Christine E. Bandtlow
Dept. of Neurobiochemistry
Institute of Medical Chemistry
and Biochemistry
Fritz-Pregal-Str. 3
University of Innsbruck
A-6020 Innsbruck
Austria

Wolfgang Brück
Institute for Neuropathology
Georg-August-University Göttingen
Robert-Koch-Str. 40
D-37075 Göttingen
Germany

Joaquin Castilla
University of Texas Medical Branch
301 University Boulevard
Galveston, TX 77555
USA

Ibolja Cernak
Department of Neuroscience
Georgetown University Medical Center
Research Bld, Room EP04
Washington, D.C. 20007
USA

Volkmar Dietz
Spinal Cord Injury Center
University Hospital Balgrist
Forchstr. 340
CH-8008 Zürich
Switzerland

Ulrich Dirnagl
Department of Neurology
Humboldt-University Berlin
Schumannstr. 20–21
D-10098 Berlin
Germany

Alan I. Faden
Department of Neuroscience
Georgetown University Medical Center
Research Bld, Room EP04
Washington, D.C. 20007
USA

James W. Fawcett
Brain Repair Centre
Cambridge University
Cambridge CB2 2PY
United Kingdom

Georg Haase
Institut de Neurobiologie
de la Méditerranée
Campus de Luminy
F-13288 Marseille Cedex 09
France

Christian Haass
Laboratory of Alzheimer's and
Parkinson's Disease Research
Department of Biochemistry
Ludwig Maximilians University
of Munich
Schillerstr. 44
D-80336 Munich
Germany

Claudio Hetz
University of Texas Medical Branch
301 University Boulevard
Galveston, TX 77555
USA
and
Instituto de Ciencias Biomédicas
Universidad de Chile
Santiago, Chile

Konstantin-A. Hossmann
Max-Planck-Institut für neurologische
Forschung
Gleueler Str. 50
D-50931 Köln
Germany

Sebastian Jessberger
Formerly MDC Berlin-Buch, now
The Salk Institute for Biological Studies
10010 North Torrey Pines Rd.
La Jolla, CA 92037
USA

Philipp J. Kahle
Laboratory of Alzheimer's and
Parkinson's Disease Research
Department of Biochemistry
Ludwig Maximilians University
of Munich
Schillerstr. 44
D-80336 Munich
Germany

Gerd Kempermann
Research Group „Neuronal Stem Cells“
Max Delbrück Centre for Molecular
Medicine (MDC) Berlin-Buch
Robert-Rössle-Str. 10
D-13125 Berlin
Germany

Deniz Kirik MD, PhD
Assistant Professor of Neurobiology
Wallenberg Neuroscience Center
Lund University
BMC A11
S-22184 Lund
Sweden

Laura Korhonen
McLean Hospital
Harvard Medical School
115 Mill Street Belmont
Massachusetts 02478
USA

Paul M. Leavitt IV
Department of Neuroscience
Georgetown University Medical Center
Research Bld, Room EP04
Washington, D.C. 20007
USA

Dan Lindholm
 Department of Neuroscience,
 Neurobiology
 Uppsala University
 Husargatan 3
 Biomedical Centre, Box 587
 S-75123 Uppsala
 Sweden

Stuart A. Lipton
 The Burnham Institute
 The Salk Institute for Biological Studies
 The Scripps Research Institute,
 and the University of California
 San Diego, La Jolla, California 92037
 USA

Matthew Maingay
 Wallenberg Neuroscience Center
 Lund University
 BMC A11
 S-22184 Lund
 Sweden

Andreas Meisel
 Department of Neurology
 Humboldt-University Berlin
 Schumannstr 20–21
 D-10098 Berlin
 Germany

Harald Neumann
 Head of the Neuroimmunology Unit
 European Neuroscience Institute
 Göttingen
 Waldweg 33
 D-37073 Göttingen
 Germany

Konstantin Prass
 Department of Neurology
 Humboldt-University Berlin
 Schumannstr. 20–21
 D-10098 Berlin
 Germany

Marina Romero-Ramos
 Wallenberg Neuroscience Center
 Lund University
 BMC A11
 S-22184 Lund
 Sweden

Milene Russelakis-Carneiro
 Apoxis Inc.
 18–20 Avenue de Sévelin
 CH-1004 Lausanne
 Switzerland

Jörg B. Schulz
 Department of General Neurology
 Center of Neurology and Hertie Institute
 for Clinical Brain Research
 University of Tübingen
 Hoppe-Seyler-Str. 3
 D-72076 Tübingen
 Germany

Claudio Soto
 Director Protein Misfolding
 Disorders Lab
 University of Texas Medical Branch
 301 University Boulevard
 Galveston, TX 77555
 USA

Christine Stadelmann
 Institute for Neuropathology
 Georg-August-University Göttingen
 Robert-Koch-Str. 40
 D-37075 Göttingen
 Germany

Poonam Verma
 Brain Repair Centre
 Cambridge University
 Cambridge CB2 2PY
 United Kingdom

Tilo Wolf
Department of Neurology
Humboldt-University Berlin
Schumannstr. 20–21
D-10098 Berlin
Germany

Anne D. Zurn
Department of Experimental Surgery
Lausanne University Hospital
CH-1011 Lausanne
Switzerland

I

**Neurological Disorders – Epidemiology, Clinical Overview,
and Model Systems**

1

Stroke

Andreas Meisel, Konstantin Prass, Tilo Wolf, Ulrich Dirnagl

Abstract

The current understanding of stroke pathophysiology is basically founded on experimental models. Among these, *in vitro* models with primary cultures of cerebral cells permit stroke pathophysiology to be examined on a molecular level, while animal models (mainly mouse and rat) are used to evaluate medical intervention. There is a highly complex sequence of events leading to the eventual ischemic cerebral damage that follows a well-defined spatio-temporal pattern. Overwhelming excitotoxicity leads to early necrotic cell death in what is to become the core of the infarction, while the tissue damage in the surrounding zone called penumbra happens on a longer time scale. The excitotoxic or inflammatory mechanisms are milder, bearing the biochemical hallmarks of apoptosis. The brain cells, challenged by such a large-scale assault, activate endogenous protective programs. These have been studied by experimentally inducing ischemic tolerance (i. e. ischemic preconditioning). Importantly, cerebral ischemia not only affects the brain, but also impacts other systems. For example, stroke induces dramatic immunodepression through over-activation of the sympathetic nervous system. As a result, severe bacterial infections such as pneumonia occur. The complex signaling cascades not only decide over cell survival in the brain and the neurological deficit, but also over mortality after stroke from extracerebral complications. Their ability to govern not only the maturation of the eventual infarction but also the immune system make them a promising target for intervention and the development of neuroprotective drugs.

1.1

Introduction

In the US more than 600,000 people per year suffer from strokes, and among acutely hospitalized neurological patients stroke patients make up the largest share – about 50%. Currently, there are about 4 million stroke survivors [1] in

the US. Mortality from stroke is an estimated 25 %, which makes it the third major cause of death in industrialized countries. Due to the high rate of severe permanent disability, stroke is a burden not only for the affected patients and their families, but also for national economies: In the US, it is estimated that the annual costs caused by strokes ranges between 30 and 40 billion dollars [2, 3]. In the UK, the cost of one individual patient amounts to £ 30,000 over 5 years [4].

The term stroke accommodates a variety of different conditions. About 85 % of all strokes are caused by cerebral ischemia due to vessel occlusion. Primary cerebral bleeding is rare in comparison –15%. Of the ischemic strokes, 75 % are caused by emboli, of either arterial or cardiac origin, while microvascular occlusion, i. e. hyalinosis or *in-situ* thrombosis is responsible for 20 % of cases. Hemodynamic ischemia, caused by stenoses of brain-supplying arteries, account for less than 5 % of ischemic strokes [5, 6].

The prospective risk of suffering an ischemic stroke is partially a function of social and behavioral (nutrition, tobacco use, stress) factors and longstanding disorders like hypertension, diabetes, disorders of cholesterol and lipid metabolism, and obesity. Atherosclerosis is not only the main underlying condition in ischemic stroke, but also in coronary heart disease and peripheral vascular disease. Moreover, the genetic background of affected individuals is coming under increasing scientific scrutiny, as might be expected for familial stroke conditions like CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucencephalopathy), which is characterized by relapsing subcortical ischemia. The condition is caused by a mutation in the *notch3*-gene on chromosome 19 [7, 8]. MELAS (mitochondrial encephalopathy, lactate acidosis, stroke-like episodes) is another rare familial stroke disorder, characterized by migraine, grand-mal seizures, and recurrent cortical infarctions. The condition is caused by a range of mutations in the mitochondrial genome, which explains its maternal inheritance. The severity of the phenotype depends mainly on the mutation locus and on the proportion of mutated mitochondrial genomes in the cerebral mosaic (for review see [9]). However, family and twin studies suggest that genetic factors are likely to be involved in common types of ischemic stroke, not just in rare and well defined familial stroke disorders [10–13].

A locus on chromosome 5q12 described for the Icelandic population seemed to increase stroke susceptibility significantly [14]. The responsible gene has been identified as phosphodiesterase 4D (PDE4D). The risk-conveying polymorphisms are located in the gene-regulatory part. This hints at a defect in the regulation of the encoded cAMP degrading protein [15]. Phosphodiesterase 4D belongs to a group of proteins that are drug targets in the treatment of asthma, erectile dysfunction and inflammation.

Symptoms of focal cerebral ischemia depend on the individual affected vessel with its typical supply territory. Table 1 summarizes the frequency of affection [16] and the typical clinical syndromes for the main brain arteries. Stroke mortality is rated between 20 and 30%. Unfavorable prognostic factors are old age, initial coma, papillary asymmetry, coronary heart disease and heart failure. Pyrexia and infections (pneumonia in particular) deteriorate the prognosis particularly during

the initial phase (see below). Of the surviving patients, one third improves within a week, 40% remain unchanged in their disability, and 20% deteriorate further during the first week [17].

Table 1.1 Territorial stroke syndromes.

Anterior territory		
MCA	(≈60%)	hemiparesis mainly arm, hemihypaesthesia, hemianopia, dysphasia or neglect
ACA	(4%)	hemiparesis mainly leg, urinary incontinence, apraxia
AchA	(8%)	hemiparesis, hemihypaesthesia, hemianopia
Posterior territory		
VA/BA	(10%)	vertigo, diplopia, bilateral hypaesthesia and paresis, crossed syndromes, amaurosis, ataxia, headache, coma
Cerebellum (PICA/ AICA)	(7%)	headache, ataxia, vertigo, gaze palsy, facial weakness, deafness
PCA	(9%)	hemianopia, dyslexia, visual agnosia

A great deal of our knowledge about the pathophysiology of stroke comes from experimental research. The experimental animal models follow two main paradigms: One is the model of focal cerebral ischemia as a model of ischemic stroke. The other is the model of global cerebral ischemia as model of circulatory arrest. For obvious reasons, we will focus mainly at studies of focal cerebral ischemia. The bulk of experimental studies has been carried out with rats and mice, although some primates have been used. In rodents, ischemia is mostly induced by intravascular occlusion of the MCA, using a monofilament just exceeding the critical vessel diameter. Depending on the duration of occlusion, we distinguish permanent from transient ischemia models. The latter are also used as models for spontaneous reperfusion or for the state after successful lysis therapy with recombinant tissue plasminogen activator (rtPA) in humans, respectively.

In models of cerebral ischemia perfusion to the brain is impeded by some form of manipulation. Since the essence of ischemic stroke is vascular occlusion, it is not surprising that in these models the extent of the eventual infarction can be predicted quite accurately from the degree of reduction in regional cerebral blood (rCBF) flow. Thus, if the rCBF is reduced to less than 25% of normal the likelihood of infarction in a given volume of brain tissue greater than 95%. In contrast, the likelihood of infarction is less than 5% if rCBF does not fall below 50% of normal. These thresholds have been established in comparative human PET and MRI studies [18] and correspond with experimental data from animal models [19]. Thus, the initial reduced rCBF determines the extent of the anticipated infarction. This, however, holds only with the provision that a spontaneous or therapeutic reperfusion does not take place.

We now look at ischemic infarction as the result of a complex and prolonged process of infarct maturation rather than a simple result of reduced regional perfu-

sion. As brain tissue has a high demand for oxygen and glucose, a disruption of perfusion leads to substrate depletion within few minutes, while toxic metabolites accumulate. The ensuing cellular energy deficit leads to a collapse of the established ion gradients and the membrane potential. Neurons and glial cells depolarize. Depending on the extent and the duration of this energy deficiency, the cells will suffer not only a functional but also a structural breakdown. The highly complex sequence of events within the ischemic area follows a fairly well defined stereotypic spatio-temporal pattern, which we will discuss below in more detail. The concept of the ischemic **penumbra** is crucial to the understanding of these mechanisms. The cascade of ischemic damage begins with **excitotoxicity**, the formation of reactive **oxygen free radicals**, the increasing **tissue acidosis** and the occurrence of **periinfarct-depolarizations**. It is followed by the stages of **inflammation** and programmed cell death (**apoptosis**). This is associated with **DNA damage** that, in turn, induces **DNA repair programs**. Although the process is not yet fully understood, we know that chromatin re-modeling, i. e. **epigenetic mechanisms**, and the activation of transcription factors induce complex **gene programs**. These changes initiate the expression of destructive proteins involved in inflammation and apoptosis, as well as a host of protective genes that help repair the ischemic damage. It is the activation of these protective genes that builds up **ischemic tolerance**. Among the many newly discovered protective mechanisms, **endogenous** and **exogenous cell replacement** have met with a lot of interest. Apart from these autochthonous mechanisms of the brain tissue, there are other mechanisms on a systemic scale, which bear important clinical significance. For instance, the phenomenon of **stroke-induced immunodepression** can help to understand why stroke patients are at such high risk of contracting serious bacterial infections. Neuroprotective treatment must be based on an understanding of these mechanisms.

1.2

The Penumbra Concept

In the ischemic brain, we commonly distinguish two tissue volumes – the core of the infarction and the surrounding zone, known as ischemic penumbra [20] – the underperfused and metabolically compromised margin surrounding the irrevocably damaged core. Core and penumbra are characterized by two different kinds of cell death: necrosis and apoptosis (which is also called programmed cell death or delayed neuronal cell death). The severe perfusion deficit in the core causes a breakdown of metabolic processes, cellular energy supply and ion homeostasis, which causes the cells to lose their integrity within minutes. Thus, acute necrosis of cell and tissue prevails in the core. In the penumbra, some residual perfusion is maintained by collateral vessels, which may be unable to maintain the full functional metabolism, but prevents immediate structural disintegration. However, over time, the alteration of cellular homeostasis causes more and more cells to die, and the volume of the infarction increases. The penumbra has thus to be considered as tissue at risk during the maturation of the infarct. In this region,

apoptosis and inflammatory signaling cascades play an important role. It may initially constitute 50% of the volume that will end up as infarction. The mechanisms that lead to delayed cell death within the penumbra are the subject of intense research, as they provide targets for a specific neuroprotective therapy in brain regions challenged by ischemia, but which are still viable (for a review see [19, 21]).

1.3

Excitotoxicity

The depolarization of neurons and glia due to local energy deficit causes the activation of voltage-gated calcium channels and the release of excitatory amino acids into the extracellular space. Glutamate in particular, which, under normal cellular energy conditions, would be immediately taken up pre-synaptically or through astrocytes, now remains in the extracellular space where it accumulates dramatically. Through the activation of glutamate receptors NMDA and AMPA, the intracellular Ca^{2+} level rises. Furthermore, metabotropic glutamate receptors are activated through the induction of phospholipase C (PLC) and inositol triphosphate (IP_3), and calcium is mobilized from intracellular stores.

Furthermore, the over-activation of AMPA receptors causes a rise of sodium and chloride concentrations. Altogether, the result is a massive disturbance of ion homeostasis, accompanied by passive water influx and cell edema. Ultimately, these massive changes in cell volume account for osmotic cell lysis. This lytic type of cell death, also referred to as necrosis, is primarily observed in the core of the infarction. Cells that escape this most dramatic form of disintegration, as they can not found in the core but in the penumbra where excitotoxicity may be an initiator of molecular events that lead to apoptosis and inflammation (for an overview see [21, 22]).

1.4

Oxygen Free Radicals

As a consequence of ischemia and particularly of reperfusion, reactive oxygen free radicals such as superoxide, hydrogen peroxide and hydroxyl radicals are generated. Nitric oxide is generated via the activation of the calcium-calmodulin-dependent nitric oxide synthase (NOS); it reacts with superoxide radicals and forms thus the highly reactive peroxy-nitrite radical. Further sources of oxygen free radicals in the damaged brain tissue are the breakdown products of the adenosine phosphates, which contribute to radical production via xanthine oxidase and the iron-catalyzed Haber-Weiss reaction. The many different radical species that are thus formed can react with virtually any cellular components (carbohydrates, amino acids, DNA, phospholipids) and damage them. The peroxidation of membrane lipids releases further radicals – and further glutamate. Oxygen free radicals gain even more

significance when new oxygen reaches the damaged tissue by virtue of reperfusion, or in the penumbra where oxygen supply has not ceased entirely (overview in [21, 22]).

Hypoxia itself as well as the elevated intracellular concentration of calcium ions and free radicals disrupt the function of neuronal mitochondria. Consequently, a so-called mitochondrial permeability transition pore (MPT) in the mitochondrial membrane may form. Besides impeding ATP production through loss of mitochondrial potential, the MPT leads to mitochondrial swelling, a burst of free oxygen radicals, and the release of pro-apoptotic molecules. Thus a vicious cycle of further disintegration is fuelled (see below, for review [21, 23]). This vicious cycle is counterbalanced in part by anti-oxidative enzymes like the manganese-superoxide dismutase (Mn-SOD) and the cytosolic forms of the copper-zinc superoxide dismutase (CuZn-SOD). These may prevent the breakdown of the mitochondrial membrane and, thus, the release of cytochrome C, which would be the trigger of apoptosis (see below and for review [24]).

1.5

Tissue Acidosis

In the context of stroke pathophysiology, the proton balance is intimately linked with the glucose metabolism. With reduced oxygen availability, anaerobic glycolysis as only remaining source of ATP production leads to tissue acidosis. It has long been assumed that this acidosis was one of the main noxious mechanisms in ischemic stroke. This so-called ‘lactate-acidosis-hypothesis’ is often quoted as explanation for the “glucose paradox” of cerebral ischemia. This paradox refers to the observation that excessive supply of glucose, the most important source of energy of the brain, during focal cerebral ischemia does not reduce tissue damage as one should think but, instead, augments it [25]. However, by which mechanism this happens and, in fact, whether levels of acidosis reached in brain ischemia can generate brain tissue damage at all is still far from being clear. Possibly, the pH dependent transition of Fe(III) to Fe(II) and the release of iron from molecular storages lead to a facilitation of the Haber-Weiss reaction that forms toxic free oxygen radical species (see above). Besides the production of different species of oxygen free radicals, acidosis also interferes with intracellular protein synthesis. However, the lactate-acidosis-hypothesis is not unchallenged. Particularly the fact that acidosis blocks the NMDA-receptor and thus has an anti-excitotoxic effect indicates the complexity of the role that acidosis plays in cerebral ischemia (for a review [21]).

A similarly hotly debated topic are the findings on hyperglycemia during stroke. Experimental data from animal models show a detrimental effect of hyperglycemia during focal cerebral ischemia [26–28]. Clinical data also suggest that hyperglycemia during the acute phase of stroke worsens prognosis [29–31]. Persisting hyperglycemia beyond the acute phase is also an independent prognostic factor for larger infarct volume and poorer functional outcome in stroke patients [32]. It is a matter of debate whether these observations are due to a causal relationship or if hypergly-